Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
- Address
- Paseo De La Castellana 261, 28046 Madrid, Spain
Oncology
At Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz in Madrid, Spain, the Oncology research program focuses on neoplasms and related skin and connective tissue diseases. The studies are centered on understanding disease behavior, assessing new treatment options, and improving care for people with difficult-to-treat cancers and inflammatory skin conditions.
- Research in recurrent and platinum-resistant ovarian cancer, including fallopian tube and primary peritoneal carcinoma
- Trials in endometrial cancer and recurrent cervical cancer aimed at testing new cancer therapies
- Evaluation of novel treatments for advanced gynecologic cancers with a focus on safety and effectiveness
With 15 clinical trials and 245 investigators contributing to the work, the site is actively exploring new approaches for women’s cancers, including studies designed to improve treatment response in recurrent disease.
Dermatology and Skin Disease Research
The site also conducts clinical research in skin and connective tissue diseases, with a strong emphasis on atopic dermatitis. These trials are evaluating whether newer therapies can better reduce symptoms, improve skin severity, and support longer-lasting disease control for adults and adolescents living with moderate-to-severe disease.
- Studies in atopic dermatitis focused on improving signs, symptoms, and overall disease severity
- Assessment of emerging treatments intended to maintain clinical benefit over time
- Research aimed at improving quality of life for patients with chronic inflammatory skin disease
This work reflects a broader effort at Hospital Universitario La Paz to test innovative therapies across both inflammatory and cancer-related conditions.
Experimental and Targeted Cancer Therapies
A notable part of the research portfolio involves testing new anticancer therapies for hard-to-treat gynecologic malignancies. The studies are designed to evaluate whether investigational treatments can offer meaningful benefit for patients whose cancers have returned or no longer respond well to standard care.
- First-in-human studies assessing the safety of new cancer treatments
- Trials in ARID1a-mutated ovarian, fallopian tube, and primary peritoneal carcinoma
- Research in recurrent endometrial and recurrent epithelial ovarian cancer
These studies combine drug development and treatment effectiveness research, helping define whether promising new options can move closer to routine use in oncology care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 36 therapeutic areas and 15 of 1 111 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 1 056 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 227 by active trials.
- 1Merck Sharp & Dohme LLC15active
lock +226 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC35trials
lock +135 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
lock Showing 1 of 944 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "Abdominal Aortic Aneurysm Stabilization with Truncal Cells: Controlled Clinical Trial with Historical Cohorts." | Grupo Dermatologico Y Estetico Pedro Jaen S.A. | Phase II | Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 1 111 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 60 | Unknown | 2015-11-06 | 2026-07-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.